Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.14 Average PT from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned a consensus rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued a report on the stock in the last year is $12.14.

STRO has been the topic of several analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a research note on Monday, September 16th. Truist Financial reduced their target price on shares of Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 16th. Piper Sandler reiterated an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a research report on Friday, October 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a research note on Monday, November 18th.

Sutro Biopharma Stock Down 1.5 %

Shares of STRO opened at $2.65 on Thursday. The stock’s 50-day moving average price is $3.44 and its 200 day moving average price is $3.73. Sutro Biopharma has a 12-month low of $2.45 and a 12-month high of $6.13. The firm has a market capitalization of $218.52 million, a price-to-earnings ratio of -1.65 and a beta of 1.17.

Institutional Trading of Sutro Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its stake in Sutro Biopharma by 24.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock worth $102,000 after acquiring an additional 3,578 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Sutro Biopharma by 49.1% during the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after purchasing an additional 5,373 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of Sutro Biopharma by 9.7% in the 2nd quarter. Hsbc Holdings PLC now owns 60,858 shares of the company’s stock valued at $173,000 after buying an additional 5,404 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Sutro Biopharma by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock valued at $97,000 after buying an additional 7,082 shares during the period. Finally, Gladius Capital Management LP acquired a new stake in Sutro Biopharma during the 3rd quarter worth $28,000. 96.99% of the stock is owned by institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.